Okamoto et al. [134] performed dosimetry studies in 18 patients who had received 1–4 treatment cycles of 177Lu-PSMA-I&T showing that organ and tumor-absorbed dose were comparable to 177Lu-PSMA-617. Here, FOLH1 is linked to neoplasm.